首頁 > 市場調查報告書 > 製藥

癌症生物製劑

市場調查報告書

商品編碼

1519698

2024-2032 年按治療類型、應用、最終用戶和地區分類的癌症免疫治療市場報告

Cancer Immunotherapy Market Report by Therapy Type, Application, End User, and Region 2024-2032

出版日期: 2024年07月01日 | 出版商:

IMARC | 英文 143 Pages | 商品交期: 2-3個工作天內

價格

簡介目錄圖表

IMARC Group年全球癌症免疫治療市場規模達1,189億美元。癌症病例數量的不斷增加、政府的有利舉措以及醫療保險的廣泛普及是推動市場發展的一些關鍵因素。

全球癌症免疫治療市場分析：

主要市場促進因素：由於飲食不均衡和有毒物質的攝入而導致的癌症病例不斷增加是推動市場成長的主要因素之一。除此之外，世界各地大眾對各種癌症治療方案的認知不斷增強也促進了市場的成長。

主要市場趨勢：醫療保險的廣泛可用性和便利性，以及醫療保健支出的增加，為行業投資者提供了利潤豐厚的成長機會。除此之外，人們對副作用較少的先進治療解決方案（例如免疫療法）的日益青睞正在為市場創造積極的前景。

地理格局：從區域層面來看，市場分為北美、亞太、歐洲、拉丁美洲、中東和非洲，其中北美目前在全球市場中佔據主導地位。

競爭格局：全球癌症免疫治療市場的一些領導者包括安進公司、阿斯特捷利康公司、拜耳公司、百時美施貴寶公司、禮來公司、羅氏公司、葛蘭素史克公司、強生公司、Merck KGaA、 Novartis AG、Pfizer Inc.、Sanofi SA 和Seagen Inc. 等。

挑戰和機會：不同的腫瘤類型反應不同。然而，在某些情況下，尤其是冷腫瘤免疫療法沒有反應，顯示存在抗藥性。因此，內在或獲得性抗藥性的發展對於免疫治療領域的市場參與者來說是一個巨大的挑戰，也是一個重大的機會。

全球癌症免疫治療市場趨勢

癌症盛行率增加

全球癌症病例數量的增加主要推動了癌症免疫療法市場的發展。國際癌症研究機構（IARC）估計，2020年約有1929萬名癌症病例。預計到 2030 年，這些病例將增加到 2,458 萬例。根據 GLOBOCAN 的數據，2020 年，美國約有 2,281,658 例新診斷癌症病例，612,390 人因癌症死亡。除此之外，肺癌和乳癌是個體中最常見的兩種癌症。加拿大癌症協會（CCS）表示，2020年，近29,800名加拿大人被診斷出罹患肺癌，佔所有新發癌症病例的13%。預計約 21,200 名加拿大人將死於肺癌，佔 2020 年所有癌症死亡人數的 25%。因此，對有效和持久的癌症治療的需求不斷成長，預計將為整個市場提供利潤豐厚的成長機會。

新型免疫療法的批准不斷增加

各個主要市場參與者正在廣泛投資於研發活動，以開發和引進先進、更有效的免疫療法。根據國家臨床試驗（NCT）註冊中心的數據，截至 2020 年 9 月 8 日，全球有超過 1,000 項正在進行的臨床試驗，旨在開發基於免疫療法的癌症治療。此外，許多國家的政府當局和相關監管機構正在採取措施加速新型免疫療法的核准過程，預計將進一步促進市場成長。例如，根據美國癌症研究協會發表的一篇文章，2023年7月，FDA批准quizartinib（Vanflyta）用於治療新診斷的急性髓性白血病（AML）的不同階段。 Quizartinib 專注於 FLT3，這是一種在大約三分之一的 AML 病例中發生扭曲的激酶。同樣，2021年5月，美國FDA批准安進公司的LUMAKRAS（Sotorasib）用於治療KRAS G12C患者，該患者涉及突變的局部晚期或轉移性非小細胞肺癌（NSCLC）。 LUMAKRAS 是第一個也是唯一一個針對 NSCLC 的標靶治療藥物。預計此類發展將推動未來幾年癌症免疫治療市場的成長。

製藥公司與研究機構之間的夥伴關係與合作

主要參與者正在採取各種策略性措施來推出新產品，這為整體市場創造了積極的前景。例如，2023 年 9 月，Immatics 和 Moderna 策略合作開發 Oncology Therapeutics。此次合作包括對 Immatics 研究性 PRAME203 TCRT 與 Moderna 正在開發的 MARTE mRNA 癌症疫苗的結合進行評估。此外，2023年8月，FBD Biologics Limited與上海復宏漢霖達成策略合作，共同推動新型免疫療法的開發。同樣，2023年12月，德國研究機構BioMed X宣布與日本製藥公司小野製藥有限公司開展一項新的聯合研究項目，旨在利用中性粒細胞的抗腫瘤作用來設計下一代免疫療法。安進公司、阿斯特捷利康公司、拜耳公司和禮來公司等一些市場參與者都參與了併購活動。透過併購活動，這些公司正在擴大其地理範圍並進入新的領域。反過來，預計這將在預測期內增加癌症免疫治療市場的收入。

本報告回答的關鍵問題

癌症免疫治療市場有多大？
2024-2032年全球癌症免疫治療市場的預期成長率是多少？
推動全球癌症免疫治療市場的關鍵因素是什麼？
COVID-19 對全球癌症免疫治療市場有何影響？
根據治療類型，全球癌症免疫治療市場的細分如何？
基於應用的全球癌症免疫治療市場的詳細情形如何？
基於最終用戶的全球癌症免疫治療市場的詳細情形如何？
癌症免疫治療市場最大的地區是哪一個？
全球癌症免疫治療市場的主要參與者/公司有哪些？

The global cancer immunotherapy market size reached US$ 118.9 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 261.0 Billion by 2032, exhibiting a growth rate (CAGR) of 8.92% during 2024-2032. The growing number of cancer cases, favorable government initiatives, and wide availability of medical insurance represent some of the key factors driving the market.

Global Cancer Immunotherapy Market Analysis:

Major Market Drivers: The increasing cases of cancer on account of a poor balanced diet and consumption of toxic substances is one of the primary factors driving the growth of the market. In addition to this, the growing awareness about various cancer treatment options among the masses across the world is also contributing to the market growth.

Key Market Trends: The wide availability and easy access to medical insurance, along with the increasing healthcare expenditures, is offering lucrative growth opportunities to industry investors. In addition to this, the emerging preference for advanced treatment solutions with fewer side effects, like immunotherapy, is creating a positive outlook for the market.

Geographical Landscape: On a regional level, the market has been classified into North America, Asia-Pacific, Europe, Latin America, and Middle East and Africa, where North America currently dominates the global market.

Competitive Landscape: Some of the leading players in the global cancer immunotherapy market include Amgen Inc., AstraZeneca plc, Bayer AG, Bristol-Myers Squibb Company, Eli Lilly and Company, F. Hoffmann-La Roche AG, GSK plc, Johnson & Johnson, Merck KGaA, Novartis AG, Pfizer Inc., Sanofi S.A, and Seagen Inc., among others.

Challenges and Opportunities: Different tumor types respond differently. However, in some cases, especially cold tumors immunotherapy is unresponsive, suggesting the presence of resistance. Hence, the development of intrinsic or acquired resistance is a big challenge as well as a significant opportunity for the market players in the immunotherapy field.

Global Cancer Immunotherapy Market Trends

Increasing Prevalence of Cancer

The rising number of cancer cases across the world is primarily driving the market for cancer immunotherapies. The International Agency for Research on Cancer (IARC) estimated that, in the year 2020, there were about 19.29 million cancer cases. These cases are projected to increase to 24.58 million cases by 2030. Such a substantial growth in cancer cases is augmenting the demand for effective treatment solutions like immunotherapies. According to GLOBOCAN, in 2020, there were approximately 2,281,658 new cancer cases diagnosed and 612,390 deaths due to cancer alone in the United States. In addition to this, lung cancer and breast cancer are two of the most common cancers found among individuals. The Canadian Cancer Society (CCS) stated that in 2020, nearly 29,800 Canadians were diagnosed with lung cancer, which accounted for 13% of all new cancer cases. About 21,200 Canadians were expected to die from lung cancer, which represented 25% of all cancer deaths in 2020. This indicates an inflating need for effective and more advanced cancer immunotherapy. Thus, the increasing demand for effective and lasting cancer treatment is anticipated to offer lucrative growth opportunities to the overall market.

Rising Approval of Novel Immunotherapies

Various key market players are extensively investing in research and development activities to develop and introduce advanced and more effective immunotherapies. According to the National Clinical Trials (NCT) Registry, as of September 8, 2020, there were more than 1,000 ongoing clinical trials across the world for the development of cancer treatment with immune-based therapies. Moreover, government authorities and concerned regulators of numerous nations are taking initiatives to expedite the approval process of novel immunotherapies, which is anticipated to further catalyze the market growth. For instance, according to an article published by the American Association for Cancer Research, in July 2023, the FDA approved quizartinib (Vanflyta) for treating different phases of newly diagnosed acute myeloid leukemia (AML). Quizartinib focuses on FLT3, a kinase that goes twisted in about one-third of AML cases. Similarly, in May 2021, the US FDA approved Amgen's LUMAKRAS (Sotorasib) for the treatment of patients with KRAS G12C, which involves mutated locally advanced or metastatic non-small cell lung cancer (NSCLC). LUMAKRAS is the first and only targeted treatment for NSCLC. Such developments are expected to propel the cancer immunotherapy market growth in the coming years.

Partnerships and Collaborations between Pharmaceuticals and Research Institutions

Various Strategic initiatives are being undertaken by major players to launch new products, which is creating a positive outlook for the overall market. For instance, in September 2023, Immatics and Moderna strategically collaborated to develop Oncology Therapeutics. The collaboration includes an assessment of Immatics investigational PRAME203 TCRT in combination with the MARTE mRNA cancer vaccine being developed by Moderna. Moreover, in August 2023, FBD Biologics Limited and Shanghai Henlius Biotech, Inc. entered into a strategic collaboration to boost the development of new immunotherapies. Similarly, in December 2023, BioMed X, a German research institution, announced a new joint research project with Ono Pharmaceutical Co. Ltd, a Japanese pharmaceutical company, to design next-generation immunotherapies by leveraging the antitumor effects of neutrophils. Several market players, such as Amgen Inc., AstraZeneca plc, Bayer AG, and Eli Lilly and Company, are involved in merger and acquisition activities. Through M&A activity, these companies are expanding their geographic reach and entering new territories. This, in turn, is projected to bolster the cancer immunotherapy market revenue over the forecasted period.

Key Market Segmentation:

IMARC Group provides an analysis of the key trends in each sub-segment of the market report, along with forecasts at the global, regional and country levels from 2024-2032. Our report has categorized the market based on therapy type, application and end user.

Breakup by Therapy Type:

Monoclonal Antibodies

Cancer Vaccines

Checkpoint Inhibitors

Immunomodulators

Others

Currently, monoclonal antibodies hold the majority of the total market share

The report has provided a detailed breakup and analysis of the market based on the therapy type. This includes monoclonal antibodies, cancer vaccines, checkpoint inhibitors, immunomodulators, and others. According to the report, monoclonal antibodies represented the largest segment.

Increasing investment for research and development activities of monoclonal antibodies is opening new avenues for the growth of companies in the oncology therapeutics space. Monoclonal antibodies are extensively being studied for their therapeutic effects against various types of cancers. For instance, in August 2023, FDA approved Talvey to treat adult patients with relapsed or refractory multiple myeloma who have received at least four prior lines of treatment, including proteasome inhibitors, immunomodulatory agents and an antiCD38 monoclonal antibody.

Breakup by Application:

Lung Cancer

Breast Cancer

Colorectal Cancer

Melanoma

Prostate Cancer

Head and Neck Cancer

Others

Among these, lung cancer currently exhibits a clear dominance in the market

A detailed breakup and analysis of the market based on the application has also been provided in the report. This includes lung cancer, breast cancer, colorectal cancer, melanoma, prostate cancer, head and neck cancer, and others. According to the report, lung cancer accounted for the largest market share.

According to cancer immunotherapy market overview, the lung cancer segment accounted for the largest revenue share in the market. This can be attributed to the increasing prevalence of lung malignancies, the escalating adoption of immunotherapy, and the presence of a robust pipeline of investigational candidates. Furthermore, rising product approval and new product launches also providing a positive outlook to the market. For instance, in November 2023, the US Food and Drug Administration (FDA) granted marketing authorizations to Augtyro (Bristol, Inc.) for the treatment of locally refractory or metastatic Non-Small Cell Lung Cancer (NSCLC) with Repotrectinib.

Breakup by End User:

Hospitals

Cancer Research Centers

Clinics

Others

Hospitals account for the largest market share

A detailed breakup and analysis of the market based on the end user has also been provided in the report. This includes hospitals, cancer research centers, clinics, and others. According to the report, hospitals accounted for the largest market share.

Growing cases of cancer, increasing treatment rates, along with a large number of hospitals offering immunotherapies are contributing to a rise in the number of patients admitted to a hospital. To treat cancer, hospitals are increasingly utilizing immunotherapies. According to an article published by the National Cancer Institute, in April 2023, in the U.S. 25% of patients died in a hospital, with 62% hospitalized at least once in the last month of life for the cancer treatments.

Breakup by Regional:

North America

United States

Canada

Asia-Pacific

China

Japan

India

South Korea

Australia

Indonesia

Others

Europe

Germany

France

United Kingdom

Italy

Spain

Russia

Others

Latin America

Brazil

Mexico

Others

Middle East and Africa

North America currently dominates the global market.

The report has also provided a comprehensive analysis of all the major regional markets, which include North America (the United States and Canada); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa. According to the report, North America (the United States and Canada) was the largest market for cancer immunotherapy.

The growth in the region can be attributed to the growing number of patients suffering from cancer, the rising development of bioinformatic tools, and favorable government initiatives. According to GLOBOCAN, in the US, there were an estimated 2,281,658 new cancer cases diagnosed and 612,390 deaths due to cancer in the year 2020. Moreover, the presence of key players in this region is also contributing to the growth of the market. According to an article published by Elsevier Ltd., in April 2023, the US National Cancer Institute published its expected national cancer plan, a roadmap, and calls to action on improving all stages of care for those suffering from cancer.

Competitive Landscape:

The market research report has provided a comprehensive analysis of the competitive landscape. Detailed profiles of all major companies have also been provided. Some of the key players in the market include:

Amgen Inc.

AstraZeneca plc

Bayer AG

Bristol-Myers Squibb Company

Eli Lilly and Company

F. Hoffmann-La Roche AG

GSK plc

Johnson & Johnson

Merck KGaA

Novartis AG

Pfizer Inc.

Sanofi S.A

Seagen Inc.

(Please note that this is only a partial list of the key players, and the complete list is provided in the report.)

Global Cancer Immunotherapy Market Recent Developments

December 2023: Oxford University Hospitals launched a new mRNA cancer vaccine trial for patients with head and neck cancers.

December 2023: BioMed X, a German research institution announced a new joint research project with Ono Pharmaceutical Co. Ltd, a Japanese pharmaceutical company, to design next-generation immunotherapies by leveraging the antitumor effects of neutrophils.

July 2023: Spanish researchers at Cima University of Navarra developed a new immunotherapy combination for liver cancer. This therapy improves efficacy in animal models of hepatocellular carcinoma. This is a proof of concept that lays the foundations for the application of this treatment in patients with the most common liver cancer.

Key Questions Answered in This Report

1. How big is the cancer immunotherapy market?
2. What is the expected growth rate of the global cancer immunotherapy market during 2024-2032?
3. What are the key factors driving the global cancer immunotherapy market?
4. What has been the impact of COVID-19 on the global cancer immunotherapy market?
5. What is the breakup of the global cancer immunotherapy market based on the therapy type?
6. What is the breakup of the global cancer immunotherapy market based on the application?
7. What is the breakup of the global cancer immunotherapy market based on end user?
8. Which is the largest region in the cancer immunotherapy market?
9. Who are the key players/companies in the global cancer immunotherapy market?

1 Preface

2 Scope and Methodology

2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
- 2.3.1 Primary Sources
- 2.3.2 Secondary Sources
2.4 Market Estimation
- 2.4.1 Bottom-Up Approach
- 2.4.2 Top-Down Approach
2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

4.1 Overview
4.2 Key Industry Trends

5 Global Cancer Immunotherapy Market

5.1 Market Overview
5.2 Market Performance
5.3 Impact of COVID-19
5.4 Market Forecast

6 Market Breakup by Therapy Type

6.1 Monoclonal Antibodies
- 6.1.1 Market Trends
- 6.1.2 Market Forecast
6.2 Cancer Vaccines
- 6.2.1 Market Trends
- 6.2.2 Market Forecast
6.3 Checkpoint Inhibitors
- 6.3.1 Market Trends
- 6.3.2 Market Forecast
6.4 Immunomodulators
- 6.4.1 Market Trends
- 6.4.2 Market Forecast
6.5 Others
- 6.5.1 Market Trends
- 6.5.2 Market Forecast

7 Market Breakup by Application

7.1 Lung Cancer
- 7.1.1 Market Trends
- 7.1.2 Market Forecast
7.2 Breast Cancer
- 7.2.1 Market Trends
- 7.2.2 Market Forecast
7.3 Colorectal Cancer
- 7.3.1 Market Trends
- 7.3.2 Market Forecast
7.4 Melanoma
- 7.4.1 Market Trends
- 7.4.2 Market Forecast
7.5 Prostate Cancer
- 7.5.1 Market Trends
- 7.5.2 Market Forecast
7.6 Head and Neck Cancer
- 7.6.1 Market Trends
- 7.6.2 Market Forecast
7.7 Others
- 7.7.1 Market Trends
- 7.7.2 Market Forecast

8 Market Breakup by End User

8.1 Hospitals
- 8.1.1 Market Trends
- 8.1.2 Market Forecast
8.2 Cancer Research Centers
- 8.2.1 Market Trends
- 8.2.2 Market Forecast
8.3 Clinics
- 8.3.1 Market Trends
- 8.3.2 Market Forecast
8.4 Others
- 8.4.1 Market Trends
- 8.4.2 Market Forecast

9 Market Breakup by Region

9.1 North America
- 9.1.1 United States
  - 9.1.1.1 Market Trends
  - 9.1.1.2 Market Forecast
- 9.1.2 Canada
  - 9.1.2.1 Market Trends
  - 9.1.2.2 Market Forecast
9.2 Asia-Pacific
- 9.2.1 China
  - 9.2.1.1 Market Trends
  - 9.2.1.2 Market Forecast
- 9.2.2 Japan
  - 9.2.2.1 Market Trends
  - 9.2.2.2 Market Forecast
- 9.2.3 India
  - 9.2.3.1 Market Trends
  - 9.2.3.2 Market Forecast
- 9.2.4 South Korea
  - 9.2.4.1 Market Trends
  - 9.2.4.2 Market Forecast
- 9.2.5 Australia
  - 9.2.5.1 Market Trends
  - 9.2.5.2 Market Forecast
- 9.2.6 Indonesia
  - 9.2.6.1 Market Trends
  - 9.2.6.2 Market Forecast
- 9.2.7 Others
  - 9.2.7.1 Market Trends
  - 9.2.7.2 Market Forecast
9.3 Europe
- 9.3.1 Germany
  - 9.3.1.1 Market Trends
  - 9.3.1.2 Market Forecast
- 9.3.2 France
  - 9.3.2.1 Market Trends
  - 9.3.2.2 Market Forecast
- 9.3.3 United Kingdom
  - 9.3.3.1 Market Trends
  - 9.3.3.2 Market Forecast
- 9.3.4 Italy
  - 9.3.4.1 Market Trends
  - 9.3.4.2 Market Forecast
- 9.3.5 Spain
  - 9.3.5.1 Market Trends
  - 9.3.5.2 Market Forecast
- 9.3.6 Russia
  - 9.3.6.1 Market Trends
  - 9.3.6.2 Market Forecast
- 9.3.7 Others
  - 9.3.7.1 Market Trends
  - 9.3.7.2 Market Forecast
9.4 Latin America
- 9.4.1 Brazil
  - 9.4.1.1 Market Trends
  - 9.4.1.2 Market Forecast
- 9.4.2 Mexico
  - 9.4.2.1 Market Trends
  - 9.4.2.2 Market Forecast
- 9.4.3 Others
  - 9.4.3.1 Market Trends
  - 9.4.3.2 Market Forecast
9.5 Middle East and Africa
- 9.5.1 Market Trends
- 9.5.2 Market Breakup by Country
- 9.5.3 Market Forecast

10 SWOT Analysis

10.1 Overview
10.2 Strengths
10.3 Weaknesses
10.4 Opportunities
10.5 Threats

11 Value Chain Analysis

12 Porters Five Forces Analysis

12.1 Overview
12.2 Bargaining Power of Buyers
12.3 Bargaining Power of Suppliers
12.4 Degree of Competition
12.5 Threat of New Entrants
12.6 Threat of Substitutes

13 Price Analysis

14 Competitive Landscape

14.1 Market Structure
14.2 Key Players
14.3 Profiles of Key Players
- 14.3.1 Amgen Inc.
  - 14.3.1.1 Company Overview
  - 14.3.1.2 Product Portfolio
  - 14.3.1.3 Financials
  - 14.3.1.4 SWOT Analysis
- 14.3.2 AstraZeneca plc
  - 14.3.2.1 Company Overview
  - 14.3.2.2 Product Portfolio
  - 14.3.2.3 Financials
  - 14.3.2.4 SWOT Analysis
- 14.3.3 Bayer AG
  - 14.3.3.1 Company Overview
  - 14.3.3.2 Product Portfolio
  - 14.3.3.3 Financials
  - 14.3.3.4 SWOT Analysis
- 14.3.4 Bristol-Myers Squibb Company
  - 14.3.4.1 Company Overview
  - 14.3.4.2 Product Portfolio
  - 14.3.4.3 Financials
  - 14.3.4.4 SWOT Analysis
- 14.3.5 Eli Lilly and Company
  - 14.3.5.1 Company Overview
  - 14.3.5.2 Product Portfolio
  - 14.3.5.3 Financials
  - 14.3.5.4 SWOT Analysis
- 14.3.6 F. Hoffmann-La Roche AG
  - 14.3.6.1 Company Overview
  - 14.3.6.2 Product Portfolio
  - 14.3.6.3 SWOT Analysis
- 14.3.7 GSK plc
  - 14.3.7.1 Company Overview
  - 14.3.7.2 Product Portfolio
  - 14.3.7.3 Financials
  - 14.3.7.4 SWOT Analysis
- 14.3.8 Johnson & Johnson
  - 14.3.8.1 Company Overview
  - 14.3.8.2 Product Portfolio
  - 14.3.8.3 Financials
  - 14.3.8.4 SWOT Analysis
- 14.3.9 Merck KGaA
  - 14.3.9.1 Company Overview
  - 14.3.9.2 Product Portfolio
  - 14.3.9.3 Financials
  - 14.3.9.4 SWOT Analysis
- 14.3.10 Novartis AG
  - 14.3.10.1 Company Overview
  - 14.3.10.2 Product Portfolio
  - 14.3.10.3 Financials
  - 14.3.10.4 SWOT Analysis
- 14.3.11 Pfizer Inc.
  - 14.3.11.1 Company Overview
  - 14.3.11.2 Product Portfolio
  - 14.3.11.3 Financials
  - 14.3.11.4 SWOT Analysis
- 14.3.12 Sanofi S.A
  - 14.3.12.1 Company Overview
  - 14.3.12.2 Product Portfolio
  - 14.3.12.3 Financials
  - 14.3.12.4 SWOT Analysis
- 14.3.13 Seagen Inc.
  - 14.3.13.1 Company Overview
  - 14.3.13.2 Product Portfolio
  - 14.3.13.3 Financials
  - 14.3.13.4 SWOT Analysis

簡介目錄圖表

List of Figures

Figure 1: Global: Cancer Immunotherapy Market: Major Drivers and Challenges
Figure 2: Global: Cancer Immunotherapy Market: Sales Value (in Billion US$), 2018-2023
Figure 3: Global: Cancer Immunotherapy Market Forecast: Sales Value (in Billion US$), 2024-2032
Figure 4: Global: Cancer Immunotherapy Market: Breakup by Therapy Type (in %), 2023
Figure 5: Global: Cancer Immunotherapy Market: Breakup by Application (in %), 2023
Figure 6: Global: Cancer Immunotherapy Market: Breakup by End User (in %), 2023
Figure 7: Global: Cancer Immunotherapy Market: Breakup by Region (in %), 2023
Figure 8: Global: Cancer Immunotherapy (Monoclonal Antibodies) Market: Sales Value (in Million US$), 2018 & 2023
Figure 9: Global: Cancer Immunotherapy (Monoclonal Antibodies) Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 10: Global: Cancer Immunotherapy (Cancer Vaccines) Market: Sales Value (in Million US$), 2018 & 2023
Figure 11: Global: Cancer Immunotherapy (Cancer Vaccines) Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 12: Global: Cancer Immunotherapy (Checkpoint Inhibitors) Market: Sales Value (in Million US$), 2018 & 2023
Figure 13: Global: Cancer Immunotherapy (Checkpoint Inhibitors) Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 14: Global: Cancer Immunotherapy (Immunomodulators) Market: Sales Value (in Million US$), 2018 & 2023
Figure 15: Global: Cancer Immunotherapy (Immunomodulators) Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 16: Global: Cancer Immunotherapy (Other Therapy Types) Market: Sales Value (in Million US$), 2018 & 2023
Figure 17: Global: Cancer Immunotherapy (Other Therapy Types) Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 18: Global: Cancer Immunotherapy (Lung Cancer) Market: Sales Value (in Million US$), 2018 & 2023
Figure 19: Global: Cancer Immunotherapy (Lung Cancer) Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 20: Global: Cancer Immunotherapy (Breast Cancer) Market: Sales Value (in Million US$), 2018 & 2023
Figure 21: Global: Cancer Immunotherapy (Breast Cancer) Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 22: Global: Cancer Immunotherapy (Colorectal Cancer) Market: Sales Value (in Million US$), 2018 & 2023
Figure 23: Global: Cancer Immunotherapy (Colorectal Cancer) Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 24: Global: Cancer Immunotherapy (Melanoma) Market: Sales Value (in Million US$), 2018 & 2023
Figure 25: Global: Cancer Immunotherapy (Melanoma) Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 26: Global: Cancer Immunotherapy (Prostate Cancer) Market: Sales Value (in Million US$), 2018 & 2023
Figure 27: Global: Cancer Immunotherapy (Prostate Cancer) Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 28: Global: Cancer Immunotherapy (Head and Neck Cancer) Market: Sales Value (in Million US$), 2018 & 2023
Figure 29: Global: Cancer Immunotherapy (Head and Neck Cancer) Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 30: Global: Cancer Immunotherapy (Other Applications) Market: Sales Value (in Million US$), 2018 & 2023
Figure 31: Global: Cancer Immunotherapy (Other Applications) Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 32: Global: Cancer Immunotherapy (Hospitals) Market: Sales Value (in Million US$), 2018 & 2023
Figure 33: Global: Cancer Immunotherapy (Hospitals) Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 34: Global: Cancer Immunotherapy (Cancer Research Centers) Market: Sales Value (in Million US$), 2018 & 2023
Figure 35: Global: Cancer Immunotherapy (Cancer Research Centers) Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 36: Global: Cancer Immunotherapy (Clinics) Market: Sales Value (in Million US$), 2018 & 2023
Figure 37: Global: Cancer Immunotherapy (Clinics) Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 38: Global: Cancer Immunotherapy (Other End Users) Market: Sales Value (in Million US$), 2018 & 2023
Figure 39: Global: Cancer Immunotherapy (Other End Users) Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 40: North America: Cancer Immunotherapy Market: Sales Value (in Million US$), 2018 & 2023
Figure 41: North America: Cancer Immunotherapy Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 42: United States: Cancer Immunotherapy Market: Sales Value (in Million US$), 2018 & 2023
Figure 43: United States: Cancer Immunotherapy Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 44: Canada: Cancer Immunotherapy Market: Sales Value (in Million US$), 2018 & 2023
Figure 45: Canada: Cancer Immunotherapy Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 46: Asia-Pacific: Cancer Immunotherapy Market: Sales Value (in Million US$), 2018 & 2023
Figure 47: Asia-Pacific: Cancer Immunotherapy Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 48: China: Cancer Immunotherapy Market: Sales Value (in Million US$), 2018 & 2023
Figure 49: China: Cancer Immunotherapy Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 50: Japan: Cancer Immunotherapy Market: Sales Value (in Million US$), 2018 & 2023
Figure 51: Japan: Cancer Immunotherapy Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 52: India: Cancer Immunotherapy Market: Sales Value (in Million US$), 2018 & 2023
Figure 53: India: Cancer Immunotherapy Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 54: South Korea: Cancer Immunotherapy Market: Sales Value (in Million US$), 2018 & 2023
Figure 55: South Korea: Cancer Immunotherapy Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 56: Australia: Cancer Immunotherapy Market: Sales Value (in Million US$), 2018 & 2023
Figure 57: Australia: Cancer Immunotherapy Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 58: Indonesia: Cancer Immunotherapy Market: Sales Value (in Million US$), 2018 & 2023
Figure 59: Indonesia: Cancer Immunotherapy Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 60: Others: Cancer Immunotherapy Market: Sales Value (in Million US$), 2018 & 2023
Figure 61: Others: Cancer Immunotherapy Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 62: Europe: Cancer Immunotherapy Market: Sales Value (in Million US$), 2018 & 2023
Figure 63: Europe: Cancer Immunotherapy Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 64: Germany: Cancer Immunotherapy Market: Sales Value (in Million US$), 2018 & 2023
Figure 65: Germany: Cancer Immunotherapy Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 66: France: Cancer Immunotherapy Market: Sales Value (in Million US$), 2018 & 2023
Figure 67: France: Cancer Immunotherapy Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 68: United Kingdom: Cancer Immunotherapy Market: Sales Value (in Million US$), 2018 & 2023
Figure 69: United Kingdom: Cancer Immunotherapy Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 70: Italy: Cancer Immunotherapy Market: Sales Value (in Million US$), 2018 & 2023
Figure 71: Italy: Cancer Immunotherapy Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 72: Spain: Cancer Immunotherapy Market: Sales Value (in Million US$), 2018 & 2023
Figure 73: Spain: Cancer Immunotherapy Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 74: Russia: Cancer Immunotherapy Market: Sales Value (in Million US$), 2018 & 2023
Figure 75: Russia: Cancer Immunotherapy Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 76: Others: Cancer Immunotherapy Market: Sales Value (in Million US$), 2018 & 2023
Figure 77: Others: Cancer Immunotherapy Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 78: Latin America: Cancer Immunotherapy Market: Sales Value (in Million US$), 2018 & 2023
Figure 79: Latin America: Cancer Immunotherapy Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 80: Brazil: Cancer Immunotherapy Market: Sales Value (in Million US$), 2018 & 2023
Figure 81: Brazil: Cancer Immunotherapy Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 82: Mexico: Cancer Immunotherapy Market: Sales Value (in Million US$), 2018 & 2023
Figure 83: Mexico: Cancer Immunotherapy Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 84: Others: Cancer Immunotherapy Market: Sales Value (in Million US$), 2018 & 2023
Figure 85: Others: Cancer Immunotherapy Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 86: Middle East and Africa: Cancer Immunotherapy Market: Sales Value (in Million US$), 2018 & 2023
Figure 87: Middle East and Africa: Cancer Immunotherapy Market: Breakup by Country (in %), 2023
Figure 88: Middle East and Africa: Cancer Immunotherapy Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 89: Global: Cancer Immunotherapy Industry: SWOT Analysis
Figure 90: Global: Cancer Immunotherapy Industry: Value Chain Analysis
Figure 91: Global: Cancer Immunotherapy Industry: Porter's Five Forces Analysis

List of Tables

Table 1: Global: Cancer Immunotherapy Market: Key Industry Highlights, 2023 and 2032
Table 2: Global: Cancer Immunotherapy Market Forecast: Breakup by Therapy Type (in Million US$), 2024-2032
Table 3: Global: Cancer Immunotherapy Market Forecast: Breakup by Application (in Million US$), 2024-2032
Table 4: Global: Cancer Immunotherapy Market Forecast: Breakup by End User (in Million US$), 2024-2032
Table 5: Global: Cancer Immunotherapy Market Forecast: Breakup by Region (in Million US$), 2024-2032
Table 6: Global: Cancer Immunotherapy Market: Competitive Structure
Table 7: Global: Cancer Immunotherapy Market: Key Players

02-2729-4219

+886-2-2729-4219